<DOC>
	<DOCNO>NCT01121588</DOCNO>
	<brief_summary>This Phase 1 trial evaluate safety efficacy crizotinib patient tumor except non-small cell lung cancer positive ALK .</brief_summary>
	<brief_title>An Investigational Drug , Crizotinib ( PF-02341066 ) , Is Being Studied In Tumors , Except Non-Small Cell Lung Cancer , That Are Positive For Anaplastic Lymphoma Kinase ( ALK )</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Crizotinib</mesh_term>
	<criteria>histologically cytologically proven diagnosis malignancy NSCLC positive translocation inversion event involve ALK gene locus positive ALK amplification event positive ALK activate point mutation mutation amplification involve cMet gene ALK gene concurrent treatment another therapeutic clinical trial prior therapy specifically direct ALK</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>neoplasm malignant</keyword>
	<keyword>lymphoma</keyword>
	<keyword>neuroblastoma</keyword>
	<keyword>Crizotinib</keyword>
	<keyword>anaplastic lymphoma kinase</keyword>
	<keyword>ALK</keyword>
</DOC>